95 related articles for article (PubMed ID: 18079623)
61. [Home chemotherapy and/or outpatient chemotherapy for patient with advanced gastric cancer].
Sato A; Yamamoto W; Takebuchi K; Hiratsuka N; Tadokoro K; Ushio J
Nihon Rinsho; 2001 Apr; 59 Suppl 4():616-20. PubMed ID: 11424453
[No Abstract] [Full Text] [Related]
62. Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer.
Yang L; Jiang X; Yan H; Li Y; Zhen H; Chang B; Kariminia S; Li Q
BMC Gastroenterol; 2018 Apr; 18(1):43. PubMed ID: 29609559
[TBL] [Abstract][Full Text] [Related]
63. [Irinotecan as second-line chemotherapy for 5-FU-resistant gastric cancer with disseminated intravascular coagulation: a case report].
Oda H; Mizuno T; Yamashita Y; Nomura H; Saito K; Tamaru S; Kageyama S; Katayama N
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1517-20. PubMed ID: 21918353
[TBL] [Abstract][Full Text] [Related]
64. Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials.
Wang DL; Gu DY; Huang HY; Xu Z; Chen JF
World J Gastroenterol; 2010 Dec; 16(46):5889-94. PubMed ID: 21155012
[TBL] [Abstract][Full Text] [Related]
65. [A case of an advanced gastric cancer patient on hemodialysis achieving long-term progression-free survival after CPT-11+CDDP therapy].
Yokoyama S; Kouyama M; Kuratsune M; Imamura Y; Nakamitsu A; Fukuda Y; Ohta H
Gan To Kagaku Ryoho; 2012 May; 39(5):817-20. PubMed ID: 22584339
[TBL] [Abstract][Full Text] [Related]
66. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer.
Farhat FS
Med Oncol; 2007; 24(2):137-46. PubMed ID: 17848736
[TBL] [Abstract][Full Text] [Related]
67. [Effects of irinotecan and 5-FU combination therapy in gastric cancer--is combination therapy synergic?].
Yamada T; Furukawa K; Yokoi K; Mamada Y; Kanazawa Y; Uchida E
Gan To Kagaku Ryoho; 2010 Nov; 37(11):2125-9. PubMed ID: 21084811
[TBL] [Abstract][Full Text] [Related]
68. Phase II study on the combination of irinotecan plus cisplatin as a second-line therapy in patients with advanced or recurrent gastric cancer.
Rino Y; Yukawa N; Sato T; Oshima T; Tanabe H; Yamamoto Y; Matsukawa H; Shiraishi R; Imada T; Masuda M
Mol Clin Oncol; 2013 Jul; 1(4):749-752. PubMed ID: 24649240
[TBL] [Abstract][Full Text] [Related]
69. Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study.
Takahata T; Itoh J; Satoh T; Ishiguro A; Matsumoto Y; Tanaka S; Saitoh S; Tohno H; Fukuda S; Saijo Y; Sakata Y
Oncol Lett; 2012 Jan; 3(1):89-93. PubMed ID: 22740861
[TBL] [Abstract][Full Text] [Related]
70. [Combination therapy of a novel oral fluorouracil derivative TS-1 with low-dose cisplatin for recurrent and very advanced gastric cancer].
Nakata B; Hirakawa K
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1962-8. PubMed ID: 15570921
[TBL] [Abstract][Full Text] [Related]
71. Irinotecan in the treatment of gastric cancer.
Bugat R
Ann Oncol; 2003; 14 Suppl 2():ii37-40. PubMed ID: 12810456
[TBL] [Abstract][Full Text] [Related]
72. Bi-weekly irinotecan hydrochloride and cisplatin as a second-line chemotherapy for patients with advanced gastric cancer.
Suzuki S; Harada N; Takeo Y; Tanaka S; Hayashi T; Suzuki M; Hanyu F
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2245-8. PubMed ID: 18079623
[TBL] [Abstract][Full Text] [Related]
73. Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil.
Shimada S; Yagi Y; Kuramoto M; Aoki N; Ogawa M
Oncol Rep; 2003; 10(3):687-91. PubMed ID: 12684644
[TBL] [Abstract][Full Text] [Related]
74. Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy.
Yoshimatsu K; Kato H; Ishibashi K; Hashimoto M; Umehara A; Yokomizo H; Yoshida K; Fujimoto T; Iwasaki K; Ogawa K
Cancer Chemother Pharmacol; 2003 Dec; 52(6):465-8. PubMed ID: 12920569
[TBL] [Abstract][Full Text] [Related]
75. [Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Suzuki S; Harada N; Takeo Y; Tanaka S; Hayashi T; Suzuki M; Hanyu F
Gan To Kagaku Ryoho; 2005 Jul; 32(7):1007-10. PubMed ID: 16044963
[TBL] [Abstract][Full Text] [Related]
76. Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
Shimoyama R; Yasui H; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N; Todaka A; Tomita H; Sakamoto T; Tsushima T
Gastric Cancer; 2009; 12(4):206-11. PubMed ID: 20047125
[TBL] [Abstract][Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
